Metformin-induced changes in the gut microbiome and plasma metabolome are associated with cognition in men

[Background]: An altered gut microbiome characterized by reduced abundance of butyrate producing bacteria and reduced gene richness is associated with type 2 diabetes (T2D). An important complication of T2D is increased risk of cognitive impairment and dementia. The biguanide metformin is a commonly...

ver descrição completa

Detalhes bibliográficos
Autores: Rosell-Díaz, Marisel, Petit-Gay, Anna, Molas-Prat, Clàudia, Gallardo-Nuell, Laura, Ramió-Torrentà, Lluís, Garre-Olmo, Josep, Pérez-Brocal, Vicente, Moya, Andrés, Jové, Mariona, Pamplona, Reinald, Puig, Josep, Ramos, Rafael, Bäckhed, Fredrik, Mayneris-Perxachs, Jordi, Fernández-Real, José Manuel
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2024
País:España
Recursos:Consejo Superior de Investigaciones Científicas (CSIC)
Repositório:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/383614
Acesso em linha:http://hdl.handle.net/10261/383614
Access Level:Acceso aberto
Palavra-chave:Cognition
Type 2 diabetes
Gut microbiota
Metformin
Descrição
Resumo:[Background]: An altered gut microbiome characterized by reduced abundance of butyrate producing bacteria and reduced gene richness is associated with type 2 diabetes (T2D). An important complication of T2D is increased risk of cognitive impairment and dementia. The biguanide metformin is a commonly prescribed medication for the control of T2D and metformin treatment has been associated with a significant reduction in the risk of dementia and improved cognition, particularly in people with T2D.

Registros relacionados